New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials

Published:2020-07-21 Issue:9 Volume:29 Page:1005-1023
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Rocco Danilo¹,Gregorc Vanesa²,Della Gravara Luigi³,Lazzari Chiara²,Palazzolo Giovanni⁴,Gridelli Cesare⁵

Affiliation:

1. Department of Pulmonary Oncology, AORN Dei Colli Monaldi , Naples, Italy

2. Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele , Milan, Italy

3. Department of Experimental Medicine, Università Degli Studi Della Campania “Luigi Vanvitelli” , Caserta, Italy

4. Division of Medical Oncology, “ULSS 15 Cittadella” , Padova, Italy

5. Division of Medical Oncology, “S.G. Moscati” Hospital , Avellino, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1793956

Reference148 articles.

1. Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

2. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

3. Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

4. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

5. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors;International Journal of Molecular Sciences;2023-06-09

2. Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer;Expert Opinion on Biological Therapy;2023-03-04

3. The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology;BioMed Research International;2023-01-23

4. Immunomodulatory functions of the circ_001678/miRNA-326/ZEB1 axis in non-small cell lung cancer via the regulation of PD-1/PD-L1 pathway;Human Molecular Genetics;2022-07-15

5. Cross-Talk Between m6A- and m5C-Related lncRNAs to Construct a Novel Signature and Predict the Immune Landscape of Colorectal Cancer Patients;Frontiers in Immunology;2022-03-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3